Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance
Open Access
- 21 November 2013
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 110 (2) , 479-488
Abstract
Human head and neck squamous cell carcinoma (HNSCC) fundamentally vary in their susceptibility to different cytotoxic drugs and treatment modalities. There is at present no clinically accepted test system to predict the most effective therapy for an individual patient. Therefore, we established tumour-derived slice cultures which can be kept in vitro for at least 6 days. Upon treatment with cisplatin, docetaxel and cetuximab, slices were fixed and paraffin sections were cut for histopathological analysis. Apoptotic fragmentation, activation of caspase 3, and cell loss were observed in treated tumour slices. Counts of nuclei per field in untreated compared with treated slices deriving from the same tumour allowed estimation of the anti-neoplastic activity of individual drugs on an individual tumour. HNSCC-derived slice cultures survive well in vitro and may serve not only to improve personalised therapies but also to detect mechanisms of tumour resistance by harvesting surviving tumour cells after treatment.Keywords
This publication has 42 references indexed in Scilit:
- Aktuelle Therapieoptionen bei rezidivierenden Kopf-Hals-TumorenHNO, 2010
- The impact of stromal cell contamination on chemosensitivity testing of head and neck carcinoma.2004
- The immunosuppressant mycophenolate mofetil attenuates neuronal damage after excitotoxic injury in hippocampal slice culturesEuropean Journal of Neuroscience, 2003
- Identification of neuronal cell death in a model of degeneration in the hippocampusBrain Research Protocols, 2003
- Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)The Lancet, 2000
- Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentrationEuropean Journal of Cancer, 1996
- Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion.1993
- Quantitation of chemosensitivity in acute myelocytic leukaemiaBritish Journal of Cancer, 1983
- An assessment of a short-term tumour chemosensitivity assay in chronic lymphocytic leukaemiaBritish Journal of Cancer, 1983
- CLINICAL CORRELATIONS OF LEUKEMIC CLONOGENIC CELL CHEMOSENSITIVITY ASSESSED BY INVITRO CONTINUOUS EXPOSURE TO DRUGS1983